KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Palvella Therapeutics (PVLA) over the last 3 years, with Sep 2024 value amounting to $1.8 million.

  • Palvella Therapeutics' Shares Outstanding (Diluted Average) rose 43.22% to $1.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.8 million, marking a year-over-year increase of 43.22%. This contributed to the annual value of $64.5 million for FY2021, which is 18.48% up from last year.
  • According to the latest figures from Q3 2024, Palvella Therapeutics' Shares Outstanding (Diluted Average) is $1.8 million, which was down 0.00% from $1.8 million recorded in Q2 2024.
  • In the past 5 years, Palvella Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $74.1 million in Q2 2022 and a low of $1.1 million during Q2 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $22.2 million, with a median of $1.8 million in 2024.
  • In the last 5 years, Palvella Therapeutics' Shares Outstanding (Diluted Average) plummeted by 98.52% in 2023 and then skyrocketed by 61.22% in 2024.
  • Over the past 5 years, Palvella Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $54.5 million in 2020, then climbed by 18.48% to $64.5 million in 2021, then increased by 19.74% to $74.1 million in 2022, then tumbled by 98.52% to $1.2 million in 2023, then spiked by 43.22% to $1.8 million in 2024.
  • Its last three reported values are $1.8 million in Q3 2024, $1.8 million for Q2 2024, and $1.8 million during Q1 2024.